secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001193125-23-169612
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera's atacicept shows 43% placebo-adjusted proteinuria reduction at week 36 in Phase 2b IgAN trial
--------------------------------------------------------------------------------

- Atacicept 150 mg achieved 43% placebo-adjusted UPCR reduction (PP, p=0.003) and 35% (ITT, p=0.012).
- Patients on atacicept had stable eGFR vs. placebo decline; delta 11% (p=0.038), 5.8 mL/min/1.73 m² difference.
- Gd-IgA1 reduced 64% from baseline (p<0.0001); safety consistent with prior studies, low SAE rate (3% vs 9% placebo).
- Phase 3 ORIGIN 3 trial initiated June 2023; topline results expected H1 2025, BLA submission H2 2025.
- Company targets commercial launch in 2026 if atacicept receives FDA approval for IgAN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523169612/0001193125-23-169612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312523169612/d522707d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-169612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer